BELLUS Health Inc. [BLU]

NasdaqGS exchange. Sector: Healthcare. Industry: Biotechnology. Location Canada, Laval.

10.525 USD 👍0.295 (+2.80%)

At close Tue Sep 27 2022

1,085,809,408 USD

Marketcap

PE:.

BETA (5y):-0.550

EPS:-0.851

Profits

for 5 years

1,188%

for 3 years

254%

for 2 years

25%

for 1 year

217%

for this year

66%

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

https://www.bellushealth.com

Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.